Natriuretic peptide receptor (NPR)-A is the primary signaling receptor for atrial natriuretic peptide and brain natriuretic peptide. Ligand binding to NPR-A rapidly activates its guanylyl cyclase domain, but its rate of cGMP synthesis declines with time. This waning of activity is called homologous desensitization and is mediated in part by receptor dephosphorylation. Here, we characterize two distinct NPR-A phosphatase activities. The serine/threonine protein phosphatase inhibitor, microcystin, inhibited the desensitization of NPR-A in membrane guanylyl cyclase assays in the absence of magnesium. EDTA also inhibited the desensitization, whereas MgCl 2 stimulated the desensitization. Because the effects of microcystin and EDTA were additive, and microcystin did not block the magnesium-dependent desensitization, the targets for these agents appear to be distinct. Incubation of membranes at 37°C stimulated the dephosphorylation of NPR-A, and microcystin blocked the temperature-dependent dephosphorylation. The addition of MgCl 2 or MnCl 2 , but not CaCl 2 , further stimulated the dephosphorylation of NPR-A, and microcystin failed to inhibit this process. The desensitization required changes in the phosphorylation state of NPR-A because the guanylyl cyclase activity of a receptor variant containing glutamate substitutions at all six phosphorylation sites was unaffected by MgCl 2 , EDTA, or microcystin. Together, these data indicate that NPR-A is regulated by two distinct phosphatases, possibly including a member of the protein phosphatase 2C family. Finally, we observed that the desensitization of NPR-A in membranes from mouse kidneys and NIH3T3 cells was increased by prior exposure to atrial natriuretic peptide, suggesting that hormone binding enhances receptor dephosphorylation.
Atrial natriuretic peptide (ANP)1 and brain natriuretic peptide (BNP), found in the atria and ventricles of the heart, respectively, are cardiac hormones that counterbalance the renin-angiotensin-aldosterone system (1, 2). Acutely, they decrease blood pressure by (i) increasing renal sodium and water excretion, (ii) stimulating vascular vasorelaxation, and (iii) inhibiting aldosterone and renin secretion. Chronically, ANP inhibits the hypertrophy of cardiomyocytes (3, 4), whereas BNP inhibits pressure-induced ventricular fibrosis (5). ANP and BNP bind two distinct cell surface proteins known as the natriuretic peptide clearance receptor and NPR-A/guanylyl cyclase A (6 -10). The clearance receptor consists of an extracellular domain, a single membrane-spanning region, and only 37 intracellular amino acids. It controls the local concentrations of natriuretic peptides through receptor-mediated internalization and degradation (11) and may signal through the heterotrimeric G proteins G i and/or G o (12). Experiments conducted on mice lacking NPR-A suggest that the known cardiovascular effects of ANP and BNP are mediated through this receptor (13,14). However, a signaling function for the clearance receptor has been observed by many laboratories...